XORTX Therapeutics Inc.
Close on Oct 19, 2026
About XORTX Therapeutics
Pharmaceutical Preparations, SIC 2834
XORTX Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney disease and related conditions associated with aberrant purine metabolism and elevated uric acid. The company's lead programs utilize XORLO, an oral formulation of oxypurinol designed to inhibit xanthine oxidase. Key therapeutic programs include XRx-008 for autosomal dominant polycystic kidney disease and XRx-026 for individuals with gout who are intolerant to allopurinol. It has also explored precision medicine diagnostics and preclinical therapies targeting renal fibrosis. Its target patient populations and healthcare customers comprise individuals suffering from progressive renal disorders and gout.
The company operates primarily through research, clinical trials, and regulatory initiatives across North America and Europe, supported by global clinical development partners. Registered in British Columbia, Canada, the company maintains its operational headquarters and main office facilities in Calgary, Alberta.
Summary of the business section of XORTX Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- XORTX Therapeutics Inc.
- Founded
- 2011
- Headquarters
- Vancouver, A1
- Address
- Suite 2400 - 745 Thurlow Street V6E 0C5
- Phone
- (403) 607-2621
- Website
- xortx.com
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- December 31
- Auditor
- Smythe LLP, Vancouver, Canada
Stock & identifiers
- Ticker
- XRTX
- Exchange
- Nasdaq
- IPO date
- Sep 23, 2021
- Shares outstanding
- 7M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-5 reverse, Apr 6, 2026; 1-for-9 reverse, Nov 14, 2023; 1-for-9 reverse, Nov 10, 2023
- SEC CIK
- 1729214
- CUSIP
- 98420Q405
- ISIN
- US98420Q4055
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
XORTX Therapeutics's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of the date of this 20-F, we had two full-time employees, one part-time employee and 14 consultants.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 1, 2025 | Late filing | Notification of late filing |
| May 1, 2024 | Late filing | Notification of late filing |
| May 3, 2022 | Late filing | Notification of late filing |
| Sep 29, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |